Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer K Lue

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
The Lancet. Haematology|October 22, 2020
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to riseJennifer K Lue, Owen A O'Connor
Current Hematologic Malignancy Reports|August 17, 2018
Emerging EZH2 Inhibitors and Their Application in LymphomaJennifer K Lue, Jennifer E Amengual
Current Hematologic Malignancy Reports|June 3, 2017
Therapeutic Options for Aggressive T-Cell LymphomasJennifer K Lue, Anna Kress, Jennifer E Amengual
Annals of Lymphoma|October 20, 2021
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyondJennifer K Lue, Owen A O'Connor, Francesco Bertoni
Advances in Immunology|August 29, 2022
The role of B cells in the development, progression, and treatment of lymphomas and solid tumorsJennifer K Lue, Stephanie Downs-Canner, Jayanta Chaudhuri
Trends in Cancer|July 24, 2025
Leveraging immunologically based therapies to treat diffuse large B-cell lymphomaJennifer K Lue, Sean E Healton, Gilles A Salles
Current Oncology Reports|July 5, 2015
Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?Jennifer K Lue, Jennifer E Amengual, Owen A O'Connor
Leukemia & Lymphoma|August 11, 2023
Mature T-cell and NK-cell lymphoma involvement of the central nervous system: a single center experienceHelen Ma, Enrica Marchi, Owen A O'Connor, et al.
The Oncologist|January 18, 2021
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory LymphomaJennifer E Amengual, Jennifer K Lue, Helen Ma, et al.
The American Journal of Pathology|January 13, 2011
Mitochondrial apoptosis-induced channel (MAC) function triggers a Bax/Bak-dependent bystander effectPablo M Peixoto, Jennifer K Lue, Shin-Young Ryu, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
The Lancet. Haematology|October 22, 2020
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to riseJennifer K Lue, Owen A O'Connor
Current Hematologic Malignancy Reports|August 17, 2018
Emerging EZH2 Inhibitors and Their Application in LymphomaJennifer K Lue, Jennifer E Amengual
Current Hematologic Malignancy Reports|June 3, 2017
Therapeutic Options for Aggressive T-Cell LymphomasJennifer K Lue, Anna Kress, Jennifer E Amengual
Annals of Lymphoma|October 20, 2021
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyondJennifer K Lue, Owen A O'Connor, Francesco Bertoni
Advances in Immunology|August 29, 2022
The role of B cells in the development, progression, and treatment of lymphomas and solid tumorsJennifer K Lue, Stephanie Downs-Canner, Jayanta Chaudhuri
Trends in Cancer|July 24, 2025
Leveraging immunologically based therapies to treat diffuse large B-cell lymphomaJennifer K Lue, Sean E Healton, Gilles A Salles
Current Oncology Reports|July 5, 2015
Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?Jennifer K Lue, Jennifer E Amengual, Owen A O'Connor
Leukemia & Lymphoma|August 11, 2023
Mature T-cell and NK-cell lymphoma involvement of the central nervous system: a single center experienceHelen Ma, Enrica Marchi, Owen A O'Connor, et al.
The Oncologist|January 18, 2021
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory LymphomaJennifer E Amengual, Jennifer K Lue, Helen Ma, et al.
The American Journal of Pathology|January 13, 2011
Mitochondrial apoptosis-induced channel (MAC) function triggers a Bax/Bak-dependent bystander effectPablo M Peixoto, Jennifer K Lue, Shin-Young Ryu, et al.
Pageof 3